Grey Wolf Therapeutics is working on a fresh approach to immuno-oncology that does not directly target the immune system, but instead alters tumor cells by illuminating and priming them for immune system annihilation.
A new generation of entrepreneur is building consumer products and services - ideas that seem crazy today, and will feel intuitive in a few years. So, we’re building out a new generation of investors to attack these opportunities and deepen our consumer practice.
Antiva is working on a first-in-class treatment that, if successful, could make surgery for precancerous cervical lesions caused by the human papillomavirus unnecessary. But when it comes to making that case to investors and doctors — particularly the men who dominate those professions — it has often been an uphill battle.
We’re excited to be launching Canaan Beta, Canaan’s new $20 million seed program that aims to invest in the next wave of consumer technologies across social, eCommerce, gaming and even sectors that haven’t yet been imagined.
We at Canaan are “all in” on the notion that diversity of knowledge and experience breeds the best results. With this as our core value, PACT Pharma immediately captured our imagination and investment.
How far have loyalty programs come in actually cultivating true loyalty from consumers, as opposed to just transactions? Introducing our newest investment in Bumped, which offers the most valuable loyalty tool of all – ownership.
General Partner Wende Hutton is an industry pioneer. Partner Julie Grant chatted with Wende about today’s scientific renaissance, the importance of a team approach and the difference between active and activist investor.